



# ALL-ORAL DIRECT-ACTING ANTIVIRAL COMBINATION THERAPY: CHRONIC HEPATITIS C TREATMENT AFTER UNSUCCESSFUL THERAPY WITH DAAS AGENTS

M. Madrid González<sup>1</sup>, M. Moreno García<sup>1</sup>, J.J. Castellano-Herrador<sup>1</sup>, X. Ramis Riera<sup>1</sup>, A. Del Olmo-Revuelto<sup>1</sup> <sup>1</sup>Hospital Universitario Rio Hortega, Farmacia, Valladolid (Spain)

## **PURPOSE**

To describe retreatment of chronic HCV infection after unsuccessful therapy with DAAs regimens

## MATERIAL AND METHODS

Observational retrospective descriptive study that includes patients diagnosed with HCV who did not achieve sustained virological response 12 weeks after treatment (SVR12) after a first treatment with DAAs from September 2014 to March 2017. The variables genotype, liver fibrosis (METAVIR score), first treatment with DAAs, retreatment and SVR12 are extracted from electronic health record and the dispensing program

#### RESULTS

A total of 352 patients received treatment with DAAs from September 2014 to March 2017.

4/14 have not received yet retreatment,

14/352 did not achieve SVR12 3/14 have received treatment for 12 weeks

7/14 for 24 weeks

The results by genotype were:

Patient	Gt	Liver Fibrosis	Treatment 1	Retreatment	SVR12
1	1a	_	Simeprevir(SMV) + Sofosbuvir(SOF)	Dasabuvir(DSB) + Ombitasvir/Paritaprevir/Ritonavir(OMB/PTV/r)+Ribavirina(RBV)	YES
2	1a	F4	SMV + SOF	Ledipasvir/Sofosbuvir(LED/SOF)+RBV	YES
3	1a	F4	LED/SOF+RBV	SMV+SOF+RBV	NOT YET
4	1b	F4	SMV+ Peginterferon (PEG) + RBV	LED/SOF+RBV	YES
5	1b	F4	SOF + RBV	Daclatasvir (DCV) + SOF	YES
6	1b	F2	SMV + PEG + RBV	LED/SOF+RBV	YES
7	1b	F2	LED/SOF	DCV+SMV+SOF	NOT YET
8	1b	F3	LED/SOF	currently under evaluation	YES
9	1b	F4	SMV+SOF	DSB + OMB/PTV/r + RBV	YES
10	2	F4	SOF+RBV	DCV+SOF+RBV	YES
11	3	F2	DCV+SOF	SOF/Velpatasvir + RBV	YES
12	3a	F4	DCV+SOF+RBV	currently under evaluation	YES
13	3	F2	DCV+SOF	SOF/Velpatasvir+RBV	NOT YET
14	4	F3	LED/SOF	SMV+SOF+RBV	NOT YET

### CONCLUSIONS

In patients who failed to achieve a SVR12 with first treatment, retreatment with DAAs was very successful; however, more data about retreatments are necessary to establish strong recommendations.

23rd Congress of the EAHP Without interest conflicts